Century Therapeutics, Inc.

For the period ended Dec 31, 2024. Filed Mar 19, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 19, 2025

IPSC$1.68-7.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except share and per share amounts)


· · For the Year Ended · · For the Year Ended ·
· · December 31, 2024 · · December 31, 2023 ·

Collaboration revenue	$6,589	$2,235

Operating expenses
Research and development	107,244	92,710
General and administrative	33,155	34,706
In-process research and development	—	5,000
Impairment of long-lived assets	—	16,365
Impairment of goodwill	4,327	—
Total operating expenses	144,726	148,781

Loss from operations	(138,137)	(146,546)

Interest expense	-	(540)
Interest income	13,007	12,677
Other income (expense)	354	(383)
Total other income	13,361	11,754
Loss before provision for income taxes	(124,776)	(134,792)
Provision for income taxes	(1,790)	(1,881)
Net loss	$(126,566)	$(136,673)

Net loss per common shareBasic and Diluted	(1.61)	(2.30)
Weighted average common shares outstandingBasic and Diluted	78,648,958	59,314,389
Other comprehensive loss
Net loss	$(126,566)	$(136,673)
Unrealized gain on investments	153	2,602
Foreign currency translation (loss) gain	63	(32)
Comprehensive loss	$(126,350)	$(134,103)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.